JP2025502208A - トリプタミン組成物および方法 - Google Patents

トリプタミン組成物および方法 Download PDF

Info

Publication number
JP2025502208A
JP2025502208A JP2024541809A JP2024541809A JP2025502208A JP 2025502208 A JP2025502208 A JP 2025502208A JP 2024541809 A JP2024541809 A JP 2024541809A JP 2024541809 A JP2024541809 A JP 2024541809A JP 2025502208 A JP2025502208 A JP 2025502208A
Authority
JP
Japan
Prior art keywords
disorder
pharma
ceutically acceptable
acceptable salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502208A5 (enExample
Inventor
エル. アヴェリー,ケネス
ヘ フアン,ジェームズ
ニヴォロツキン,アレックス
エム. パテア,プラディプ
アイ. シュクール,モハメド
Original Assignee
サイビン アイアールエル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイビン アイアールエル リミテッド filed Critical サイビン アイアールエル リミテッド
Publication of JP2025502208A publication Critical patent/JP2025502208A/ja
Publication of JP2025502208A5 publication Critical patent/JP2025502208A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024541809A 2022-01-14 2023-01-13 トリプタミン組成物および方法 Pending JP2025502208A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263299599P 2022-01-14 2022-01-14
US63/299,599 2022-01-14
US202263384704P 2022-11-22 2022-11-22
US63/384,704 2022-11-22
PCT/EP2023/050702 WO2023135237A1 (en) 2022-01-14 2023-01-13 Tryptamine compositions and methods

Publications (2)

Publication Number Publication Date
JP2025502208A true JP2025502208A (ja) 2025-01-24
JP2025502208A5 JP2025502208A5 (enExample) 2026-01-20

Family

ID=85018123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541809A Pending JP2025502208A (ja) 2022-01-14 2023-01-13 トリプタミン組成物および方法

Country Status (9)

Country Link
US (1) US20250051279A1 (enExample)
EP (1) EP4463440A1 (enExample)
JP (1) JP2025502208A (enExample)
KR (1) KR20240134951A (enExample)
AU (1) AU2023207801B2 (enExample)
CA (1) CA3259235A1 (enExample)
IL (1) IL313889A (enExample)
MX (1) MX2024008691A (enExample)
WO (1) WO2023135237A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
TW202617141A (zh) 2024-07-10 2026-05-01 英商賽本英國有限公司 包含氘化n,n-二甲基色胺之醫藥組合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US6488648B1 (en) 1999-01-14 2002-12-03 Teijin Limited Device for feeding a powder in a predetermined amount and method thereof
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
AU2002340083A1 (en) 2001-09-28 2003-04-07 Kurve Technology, Inc Nasal nebulizer
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
IL312785B2 (en) * 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) * 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) * 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний
EP4221682A2 (en) * 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
EP4031529B1 (en) * 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
AU2022342266B2 (en) * 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies

Also Published As

Publication number Publication date
WO2023135237A1 (en) 2023-07-20
EP4463440A1 (en) 2024-11-20
US20250051279A1 (en) 2025-02-13
MX2024008691A (es) 2024-07-19
CA3259235A1 (en) 2023-07-20
KR20240134951A (ko) 2024-09-10
IL313889A (en) 2024-08-01
AU2023207801A1 (en) 2024-06-27
AU2023207801B2 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
US20250213527A1 (en) Formulations of psilocybin analogs and methods of use
AU2022342266B2 (en) Combination drug therapies
JP2025510942A (ja) 亜酸化窒素及び5-ht2a受容体作動薬の組み合わせ
JP2025505745A (ja) フェネチルアミン誘導体、組成物、及び使用方法
US20250236589A1 (en) Therapeutic phenethylamine compositions and methods of use
EP4279070A2 (en) Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
AU2023207801B2 (en) Tryptamine compositions and methods
KR20250097837A (ko) 펜에틸아민 화합물, 조성물, 및 사용 방법
JP2025531630A (ja) トリプタミン化合物、組成物、及び使用方法
KR20240168342A (ko) 흡입에 의한 정신자극제 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템
CN118632835A (zh) 色胺组合物和方法
CN118234708A (zh) 裸头草碱类似物的调配物和使用方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260109